Lara-Villoslada F, Sierra S, Boza J, Xaus J, Olivares M
Departamento de Inmunología y Estudios preclinicos, Puleva Biotech, Granada, España.
Nutr Hosp. 2007 Jul-Aug;22(4):496-502.
In the last decades there has been an increasing interest in the manipulation of intestinal microbiota with probiotics for the prevention and treatment of certain paediatric diseases. In addition, it has been suggested that probiotics could play a role in the development of immune system. Recent studies suggest that the administration of two probiotic strains, Lactobacillus coryniformis CECT5711 and Lactobacillus gasseri CECT5714 improves intestinal function of healthy adults and enhances the immune response. Since there are few studies reporting the use of probiotic in children, the main consumers of these products, the aim of the present study was to analyze the effects of the administration of the mentioned probiotic strains in healthy children.
30 children (age range 3-12) with no gastrointestinal pathology were included in the study. In addition to their usual diet, during the first 3 weeks they received 200 ml of a conventional yogurt containing Lactobacillus bulgaricus and Streptococcus thermophilus. During the following three weeks this yogurt was substi-tuted for 80 ml of a probiotic product (Max Defensas, Puleva Food S.L.) containing the same amounts of Streptococcus thermophilus and the L. bulgaricus was substituted by a mixture of the target probiotic strains: L. coryniformis CECT5711 and L. gasseri CECT5714. Samples of faeces and saliva were taken at the beginning of the protocol, at week 3 and at the end of the study. Intestinal microbiota, faecal citotoxicity and the inhibition of Salmonella cholerasusis ssp. cholerasuis adhesion to intestinal mucins by the faeces were analyzed. Finally, IgA concentration was determined in the faecal and saliva samples.
Tolerance of the probiotic product was good in all the children included in the study. An increase in faecal lactobacilli counts was shown at the end of the experimental protocol (P < 0,05). In addition citotoxicity of faecal samples was significantly (p < 0.05) reduced after probiotic consumption. The inhibition of S. cholerasuis adhesion to intestinal mucins was significantly higher (P < 0.05) for faecal waters from children in week 6 compared to samples form week 0 and 3. Probiotic consumption was also shown to increase IgA concentration in faeces and saliva (P < 0.05).
The consumption of a probiotic product containing L. coryniformis CECT5711 and L. gasseri CECT5714 improves intestinal flora of healthy children, enhancing the defence against gastrointestinal aggressions and infections both by inhibiting pathogen adhesion to intestinal mucins and enhancing the immune function.
在过去几十年中，人们越来越关注利用益生菌来调节肠道微生物群，以预防和治疗某些儿科疾病。此外，有研究表明益生菌可能在免疫系统发育中发挥作用。最近的研究表明，施用两种益生菌菌株，即棒状乳杆菌CECT5711和加氏乳杆菌CECT5714，可改善健康成年人的肠道功能并增强免疫反应。由于针对这些产品的主要消费群体儿童使用益生菌的研究较少，本研究的目的是分析施用上述益生菌菌株对健康儿童的影响。
本研究纳入了30名无胃肠道疾病的儿童（年龄范围3至12岁）。除日常饮食外，在最初3周内，他们每天摄入200毫升含有保加利亚乳杆菌和嗜热链球菌的传统酸奶。在接下来的三周内，将该酸奶替换为80毫升益生菌产品（Max Defensas，Puleva Food S.L.），其中嗜热链球菌的含量相同，而保加利亚乳杆菌被目标益生菌菌株混合物：棒状乳杆菌CECT5711和加氏乳杆菌CECT5714所取代。在实验方案开始时、第3周和研究结束时采集粪便和唾液样本。分析肠道微生物群、粪便细胞毒性以及粪便对猪霍乱沙门氏菌亚种猪霍乱菌粘附于肠道粘蛋白的抑制作用。最后，测定粪便和唾液样本中的IgA浓度。
本研究纳入的所有儿童对益生菌产品的耐受性良好。实验方案结束时粪便中乳酸杆菌数量增加（P < 0.05）。此外，食用益生菌后粪便样本的细胞毒性显著降低（p < 0.05）。与第0周和第3周的样本相比，第6周儿童粪便水对猪霍乱菌粘附于肠道粘蛋白的抑制作用显著更高（P < 0.05）。食用益生菌还可使粪便和唾液中的IgA浓度增加（P < 0.05）。
食用含有棒状乳杆菌CECT5711和加氏乳杆菌CECT5714的益生菌产品可改善健康儿童的肠道菌群，通过抑制病原体粘附于肠道粘蛋白和增强免疫功能，增强对胃肠道侵袭和感染的防御能力。
